Trillium Therapeutics

Trillium Therapeutics

Biotechnology, Metropolis Tower 10 Metropolis Dr Hung Hom, Cambridge, Massachusetts, United States, 11-50 Employees

trilliumtherapeutics.com

  • twitter
  • LinkedIn

phone no Phone Number: 85********

Who is TRILLIUM THERAPEUTICS

Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a mol...

Read More

map
  • Metropolis Tower 10 Metropolis Dr Hung Hom, Cambridge, Massachusetts, United States Headquarters: Metropolis Tower 10 Metropolis Dr Hung Hom, Cambridge, Massachusetts, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 8071 | NAICS Code: 621511 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from TRILLIUM THERAPEUTICS

Trillium Therapeutics Org Chart and Mapping

Employees

Ingmar Bruns

Executive Vice President and Chief Medical Officer

Bill O'Mara

Independent Clinical Data Management Consultant

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Trillium Therapeutics

Answer: Trillium Therapeutics's headquarters are located at Metropolis Tower 10 Metropolis Dr Hung Hom, Cambridge, Massachusetts, United States

Answer: Trillium Therapeutics's phone number is 85********

Answer: Trillium Therapeutics's official website is https://trilliumtherapeutics.com

Answer: Trillium Therapeutics's revenue is $10 Million to $25 Million

Answer: Trillium Therapeutics's SIC: 8071

Answer: Trillium Therapeutics's NAICS: 621511

Answer: Trillium Therapeutics has 11-50 employees

Answer: Trillium Therapeutics is in Biotechnology

Answer: Trillium Therapeutics contact info: Phone number: 85******** Website: https://trilliumtherapeutics.com

Answer: Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective do not eat signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this do not eat signal with decoy receptors, we aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access